Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer ; The lead ...
Novartis seeks to collaborate with Healthcare Professionals and Healthcare Organizations in interest of patients. As an industry we make payments or ‘transfers of value’ to Healthcare Professionals ...
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed ...
At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these treatments to as many ...
At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...
. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in Europe Scemblix ...
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results